El Hospital Universitario De Gran Canaria Dr. Negrin

The research portfolio at El Hospital Universitario De Gran Canaria Dr. Negrin includes a strong focus on hematologic diseases, especially myelofibrosis, multiple myeloma, leukemia, and lymphoma. These studies are mainly designed to evaluate new treatment options, improve disease control, and support better long-term outcomes for patients with complex blood cancers.

• Studies in myeloproliferative neoplasms such as myelofibrosis, polycythemia vera, and essential thrombocythemia
• Trials in multiple myeloma, including newly diagnosed and relapsed or refractory disease
• Research in chronic lymphocytic leukemia, acute myeloid leukemia, and related lymphoid cancers
• Evaluation of therapies aimed at improving response rates, survival, and anemia management

Much of this work reflects the site’s hematology expertise and its role in testing modern cancer therapies for patients with difficult-to-treat blood disorders.

The site is active in cardiovascular disease and metabolic disorders, with trials addressing heart failure, atherosclerotic cardiovascular disease, hypertension, and type 2 diabetes. These studies aim to determine whether new treatments can reduce major cardiac events, improve symptoms, and better protect high-risk patients.

• Studies in heart failure, including preserved and mildly reduced ejection fraction
• Trials focused on preventing myocardial infarction, stroke, and other major cardiovascular events
• Research in pulmonary arterial hypertension and related vascular conditions
• Evaluation of therapies for lipid control and broader cardiometabolic risk reduction

This research helps clarify how newer cardiovascular treatments perform in patients who already have significant risk factors or established disease.

A major part of the clinical trial activity at this hospital involves immune-mediated and inflammatory diseases, especially atopic dermatitis, hidradenitis suppurativa, psoriasis, prurigo nodularis, and vitiligo. The purpose of these studies is to test therapies that may improve symptoms, control inflammation, and support longer-lasting disease management.

• Trials in atopic dermatitis and other chronic inflammatory skin conditions
• Research on hidradenitis suppurativa and prurigo nodularis symptom control
• Studies in psoriasis, including pediatric and adult populations
• Investigations into vitiligo and other immune-related dermatologic disorders

These studies are centered on improving comfort, reducing flare-ups, and expanding treatment choices for patients with persistent skin and immune conditions.

Clinical research in nervous system diseases includes multiple sclerosis, progressive supranuclear palsy, and other neurologic conditions. The trials are intended to assess whether emerging therapies can reduce relapses, slow progression, and improve day-to-day function for people living with chronic neurologic illness.

• Studies in multiple sclerosis, including relapsing, primary progressive, and secondary progressive forms
• Research into diseases affecting movement and neurologic function
• Evaluation of therapies aimed at reducing disease activity and long-term disability

The site’s neurology-focused research adds an important dimension to its broader work in immune and inflammatory disease.

The trial program also includes digestive system diseases such as Crohn’s disease, ulcerative colitis, and acute pancreatitis. These studies are designed to improve symptom control, evaluate treatment effectiveness, and support safer management of inflammatory and acute gastrointestinal conditions.

• Trials in inflammatory bowel disease, including Crohn’s disease and ulcerative colitis
• Studies evaluating supportive care in acute pancreatitis
• Research focused on reducing disease activity and improving patient quality of life

This area reflects continued interest in both chronic gastrointestinal inflammation and urgent digestive conditions that require careful clinical management.

Beyond blood cancers, the site contributes to neoplasm research in lung cancer, breast cancer, pancreatic cancer, colorectal cancer, and urothelial carcinoma. These trials are generally aimed at improving treatment effectiveness, expanding options for surgery-related care, and supporting better outcomes in advanced or difficult-to-treat cancers.

• Studies in non-small cell lung cancer and small cell lung cancer
• Research in early breast cancer and other solid tumors
• Trials for pancreatic adenocarcinoma, colorectal cancer, and urothelial cancer
• Evaluation of therapies used before or after surgery to improve cancer control

These studies show a broad oncology profile, with attention to both common cancers and more specialized treatment pathways.

Additional research at El Hospital Universitario De Gran Canaria Dr. Negrin covers allergic diseases, immune disorders, eye inflammation, and selected supportive-care topics such as anemia, neutropenia, and vitamin D deficiency. The goal of these studies is often to improve diagnosis, manage symptoms, or evaluate how well a treatment works in specific patient groups.

• Trials in allergic rhinitis, urticaria, and other allergy-related conditions
• Research on uveitis and other inflammatory immune diseases
• Studies addressing blood-related supportive care, including anemia and neutropenia
• Evaluation of diagnostic and therapeutic approaches across multiple specialty areas

Overall, the site demonstrates a wide-ranging clinical research program with especially strong activity in hematology, while also contributing to cardiology, dermatology, neurology, gastroenterology, and oncology research.